Pharmacokinetics of liposomal curcumin (Lipocurc™) infusion: effect of co-medication in cancer patients and comparison with healthy individuals
Purpose Investigation of the impact of co-medication on the plasma levels of curcumin and tetrahydrocurcumin (THC) in cancer patients and a comparison of the pharmacokinetics of curcumin and plasma levels of THC between cancer patients and healthy individuals following intravenous infusion of Lipocu...
Uloženo v:
| Vydáno v: | Cancer chemotherapy and pharmacology Ročník 83; číslo 2; s. 265 - 275 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.02.2019
Springer Nature B.V |
| Témata: | |
| ISSN: | 0344-5704, 1432-0843, 1432-0843 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Purpose
Investigation of the impact of co-medication on the plasma levels of curcumin and tetrahydrocurcumin (THC) in cancer patients and a comparison of the pharmacokinetics of curcumin and plasma levels of THC between cancer patients and healthy individuals following intravenous infusion of Lipocurc™ (liposomal curcumin).
Methods
Correlation analysis was used to determine the impact of co-medication on infusion rate normalized plasma levels of curcumin and THC in cancer patients and to compare the plasma levels of curcumin and THC at different infusion rates between cancer patients and healthy individuals. In vitro hepatocyte and red blood cell distribution experiments were conducted with Lipocurc™ to support clinical findings. Plasma concentration time data were analyzed by the non-compartmental method to determine and compare the pharmacokinetic parameters of curcumin in cancer patients and healthy individuals.
Results
Of 44 co-medications studied, three medications targeting the renin–angiotensin system, Lisinopril, Ramipril, and Valsartan elevated plasma levels of curcumin and THC in three cancer patients infused with Lipocurc™. Cell distribution experiments indicated that the disposition of curcumin in red blood cells may be a target for elevation of the plasma levels of curcumin. Plasma levels of curcumin in cancer patients increased to a greater extent with increased infusion rate compared to healthy individuals. Upon termination of infusion, the elimination phase for curcumin was shorter with a shorter terminal half-life and smaller volume of distribution for curcumin in cancer patients compared to healthy individuals.
Conclusion
Either co-medications or health status, or both, can impact the pharmacokinetics of curcumin infusion (as Lipocurc™) in cancer patients. |
|---|---|
| AbstractList | PurposeInvestigation of the impact of co-medication on the plasma levels of curcumin and tetrahydrocurcumin (THC) in cancer patients and a comparison of the pharmacokinetics of curcumin and plasma levels of THC between cancer patients and healthy individuals following intravenous infusion of Lipocurc™ (liposomal curcumin).MethodsCorrelation analysis was used to determine the impact of co-medication on infusion rate normalized plasma levels of curcumin and THC in cancer patients and to compare the plasma levels of curcumin and THC at different infusion rates between cancer patients and healthy individuals. In vitro hepatocyte and red blood cell distribution experiments were conducted with Lipocurc™ to support clinical findings. Plasma concentration time data were analyzed by the non-compartmental method to determine and compare the pharmacokinetic parameters of curcumin in cancer patients and healthy individuals.ResultsOf 44 co-medications studied, three medications targeting the renin–angiotensin system, Lisinopril, Ramipril, and Valsartan elevated plasma levels of curcumin and THC in three cancer patients infused with Lipocurc™. Cell distribution experiments indicated that the disposition of curcumin in red blood cells may be a target for elevation of the plasma levels of curcumin. Plasma levels of curcumin in cancer patients increased to a greater extent with increased infusion rate compared to healthy individuals. Upon termination of infusion, the elimination phase for curcumin was shorter with a shorter terminal half-life and smaller volume of distribution for curcumin in cancer patients compared to healthy individuals.ConclusionEither co-medications or health status, or both, can impact the pharmacokinetics of curcumin infusion (as Lipocurc™) in cancer patients. Investigation of the impact of co-medication on the plasma levels of curcumin and tetrahydrocurcumin (THC) in cancer patients and a comparison of the pharmacokinetics of curcumin and plasma levels of THC between cancer patients and healthy individuals following intravenous infusion of Lipocurc™ (liposomal curcumin). Correlation analysis was used to determine the impact of co-medication on infusion rate normalized plasma levels of curcumin and THC in cancer patients and to compare the plasma levels of curcumin and THC at different infusion rates between cancer patients and healthy individuals. In vitro hepatocyte and red blood cell distribution experiments were conducted with Lipocurc™ to support clinical findings. Plasma concentration time data were analyzed by the non-compartmental method to determine and compare the pharmacokinetic parameters of curcumin in cancer patients and healthy individuals. Of 44 co-medications studied, three medications targeting the renin-angiotensin system, Lisinopril, Ramipril, and Valsartan elevated plasma levels of curcumin and THC in three cancer patients infused with Lipocurc™. Cell distribution experiments indicated that the disposition of curcumin in red blood cells may be a target for elevation of the plasma levels of curcumin. Plasma levels of curcumin in cancer patients increased to a greater extent with increased infusion rate compared to healthy individuals. Upon termination of infusion, the elimination phase for curcumin was shorter with a shorter terminal half-life and smaller volume of distribution for curcumin in cancer patients compared to healthy individuals. Either co-medications or health status, or both, can impact the pharmacokinetics of curcumin infusion (as Lipocurc™) in cancer patients. Investigation of the impact of co-medication on the plasma levels of curcumin and tetrahydrocurcumin (THC) in cancer patients and a comparison of the pharmacokinetics of curcumin and plasma levels of THC between cancer patients and healthy individuals following intravenous infusion of Lipocurc™ (liposomal curcumin).PURPOSEInvestigation of the impact of co-medication on the plasma levels of curcumin and tetrahydrocurcumin (THC) in cancer patients and a comparison of the pharmacokinetics of curcumin and plasma levels of THC between cancer patients and healthy individuals following intravenous infusion of Lipocurc™ (liposomal curcumin).Correlation analysis was used to determine the impact of co-medication on infusion rate normalized plasma levels of curcumin and THC in cancer patients and to compare the plasma levels of curcumin and THC at different infusion rates between cancer patients and healthy individuals. In vitro hepatocyte and red blood cell distribution experiments were conducted with Lipocurc™ to support clinical findings. Plasma concentration time data were analyzed by the non-compartmental method to determine and compare the pharmacokinetic parameters of curcumin in cancer patients and healthy individuals.METHODSCorrelation analysis was used to determine the impact of co-medication on infusion rate normalized plasma levels of curcumin and THC in cancer patients and to compare the plasma levels of curcumin and THC at different infusion rates between cancer patients and healthy individuals. In vitro hepatocyte and red blood cell distribution experiments were conducted with Lipocurc™ to support clinical findings. Plasma concentration time data were analyzed by the non-compartmental method to determine and compare the pharmacokinetic parameters of curcumin in cancer patients and healthy individuals.Of 44 co-medications studied, three medications targeting the renin-angiotensin system, Lisinopril, Ramipril, and Valsartan elevated plasma levels of curcumin and THC in three cancer patients infused with Lipocurc™. Cell distribution experiments indicated that the disposition of curcumin in red blood cells may be a target for elevation of the plasma levels of curcumin. Plasma levels of curcumin in cancer patients increased to a greater extent with increased infusion rate compared to healthy individuals. Upon termination of infusion, the elimination phase for curcumin was shorter with a shorter terminal half-life and smaller volume of distribution for curcumin in cancer patients compared to healthy individuals.RESULTSOf 44 co-medications studied, three medications targeting the renin-angiotensin system, Lisinopril, Ramipril, and Valsartan elevated plasma levels of curcumin and THC in three cancer patients infused with Lipocurc™. Cell distribution experiments indicated that the disposition of curcumin in red blood cells may be a target for elevation of the plasma levels of curcumin. Plasma levels of curcumin in cancer patients increased to a greater extent with increased infusion rate compared to healthy individuals. Upon termination of infusion, the elimination phase for curcumin was shorter with a shorter terminal half-life and smaller volume of distribution for curcumin in cancer patients compared to healthy individuals.Either co-medications or health status, or both, can impact the pharmacokinetics of curcumin infusion (as Lipocurc™) in cancer patients.CONCLUSIONEither co-medications or health status, or both, can impact the pharmacokinetics of curcumin infusion (as Lipocurc™) in cancer patients. Purpose Investigation of the impact of co-medication on the plasma levels of curcumin and tetrahydrocurcumin (THC) in cancer patients and a comparison of the pharmacokinetics of curcumin and plasma levels of THC between cancer patients and healthy individuals following intravenous infusion of Lipocurc™ (liposomal curcumin). Methods Correlation analysis was used to determine the impact of co-medication on infusion rate normalized plasma levels of curcumin and THC in cancer patients and to compare the plasma levels of curcumin and THC at different infusion rates between cancer patients and healthy individuals. In vitro hepatocyte and red blood cell distribution experiments were conducted with Lipocurc™ to support clinical findings. Plasma concentration time data were analyzed by the non-compartmental method to determine and compare the pharmacokinetic parameters of curcumin in cancer patients and healthy individuals. Results Of 44 co-medications studied, three medications targeting the renin–angiotensin system, Lisinopril, Ramipril, and Valsartan elevated plasma levels of curcumin and THC in three cancer patients infused with Lipocurc™. Cell distribution experiments indicated that the disposition of curcumin in red blood cells may be a target for elevation of the plasma levels of curcumin. Plasma levels of curcumin in cancer patients increased to a greater extent with increased infusion rate compared to healthy individuals. Upon termination of infusion, the elimination phase for curcumin was shorter with a shorter terminal half-life and smaller volume of distribution for curcumin in cancer patients compared to healthy individuals. Conclusion Either co-medications or health status, or both, can impact the pharmacokinetics of curcumin infusion (as Lipocurc™) in cancer patients. |
| Author | Bolger, Gordon T. Licollari, Albert Schönlieb, Charlotte Radl, Bianca Weiss, Lukas Sordillo, Peter P. Greil, Richard Magnes, Teresa Vcelar, Brigitta Greil-Ressler, Sigrun Majeed, Muhammed Tan, Amin |
| Author_xml | – sequence: 1 givenname: Gordon T. surname: Bolger fullname: Bolger, Gordon T. email: bolger@nucro-technics.com organization: Nucro-Technics – sequence: 2 givenname: Albert surname: Licollari fullname: Licollari, Albert organization: Nucro-Technics – sequence: 3 givenname: Amin surname: Tan fullname: Tan, Amin organization: Nucro-Technics – sequence: 4 givenname: Richard surname: Greil fullname: Greil, Richard organization: III rd Medical Department, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT), Cancer Cluster Salzburg – sequence: 5 givenname: Brigitta surname: Vcelar fullname: Vcelar, Brigitta organization: Polymun Scientific Immunbiologische Forschung GmbH – sequence: 6 givenname: Sigrun surname: Greil-Ressler fullname: Greil-Ressler, Sigrun organization: III rd Medical Department, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT) – sequence: 7 givenname: Lukas surname: Weiss fullname: Weiss, Lukas organization: III rd Medical Department, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT) – sequence: 8 givenname: Charlotte surname: Schönlieb fullname: Schönlieb, Charlotte organization: III rd Medical Department, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT) – sequence: 9 givenname: Teresa surname: Magnes fullname: Magnes, Teresa organization: III rd Medical Department, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT) – sequence: 10 givenname: Bianca surname: Radl fullname: Radl, Bianca organization: III rd Medical Department, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT) – sequence: 11 givenname: Muhammed surname: Majeed fullname: Majeed, Muhammed organization: Sabinsa Corporation – sequence: 12 givenname: Peter P. surname: Sordillo fullname: Sordillo, Peter P. email: psordillo@signpathpharma.com organization: SignPath Pharma, Inc |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30430227$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kU1uFDEQhS0URCaBA7BBltiEhZNq293tYRdF_EQaiSxgbXn8wzh0243tBmXPBbgCR-MkuDOJkCLBquTy90pV7x2hgxCDReh5A6cNQH-WAagAAo0grGdA2kdo1XBGCQjODtAKGOek7YEfoqOcrwGAN4w9QYcMOANK-xX6ebVTaVQ6fvHBFq8zjg4Pfoo5jmrAek56Hn3AJ5vaW16_f_x6hX1wc_YxvMbWOavLItKRjNZ4rUr9qATWKmib8FQbNpSMVTAVGieVfK7Ed192eGfVUHY3FTf-mzezGvJT9NjVYp_d1WP06e2bjxfvyebDu8uL8w3RrKeFcGqYga6eJNZA7VaJrejXa9cxZgRA1yrjjNCKtp0TjFGrreos511TO63asmN0sp87pfh1trnI0Wdth0EFG-csabVK0A44VPTlA_Q6zinU7W4p6DtOF-rFHTVvqxNySn5U6Ubem12Bfg_oFHNO1knty61dJSk_yAbkEqvcxyprrHKJVbZV2TxQ3g__n4buNbmy4bNNf5f-t-gPkd-2HA |
| CitedBy_id | crossref_primary_10_1111_bcpt_13477 crossref_primary_10_2147_IJN_S259628 crossref_primary_10_3390_ijms24021461 crossref_primary_10_1055_a_2604_4115 crossref_primary_10_1007_s11302_024_10023_0 crossref_primary_10_3390_pharmaceutics13122137 crossref_primary_10_3390_pharmaceutics17020276 crossref_primary_10_3389_fonc_2022_834072 crossref_primary_10_3390_molecules25225240 crossref_primary_10_3390_pharmaceutics15092223 crossref_primary_10_1055_s_0041_1735192 crossref_primary_10_3390_nano10081556 crossref_primary_10_3390_nu11092169 crossref_primary_10_3390_molecules30071495 crossref_primary_10_32604_or_2023_042228 crossref_primary_10_3390_nu11102376 crossref_primary_10_1016_j_biotechadv_2019_04_004 crossref_primary_10_1007_s11095_020_02834_8 crossref_primary_10_2147_IDR_S256773 crossref_primary_10_3390_molecules29122934 |
| Cites_doi | 10.1038/sj.bjc.6601623 10.1016/j.jchromb.2007.03.010 10.1155/2015/678218 10.1038/cmi.2010.11 10.1161/01.HYP.17.3.334 10.1016/S0006-2952(00)00489-5 10.5414/CP202076 10.1371/journal.pone.0022163 10.1371/journal.pone.0129484 10.1158/1078-0432.CCR-08-1511 10.1124/mol.113.091157 10.1080/00498254.2016.1183060 10.1158/1940-6207.CAPR-11-0308 10.1038/sj.ki.5002746 10.1016/S0731-7085(96)02024-9 10.1007/s00280-011-1749-y 10.3390/molecules191220091 10.4143/crt.2014.46.1.2 10.1016/j.ijpharm.2011.06.030 10.1111/j.1365-2125.1992.tb05644.x 10.1016/j.jchromb.2016.06.010 10.1158/0008-5472.CAN-06-3066 10.1158/1078-0432.CCR-08-0024 10.1161/01.HYP.30.1.99 10.1002/ajh.20757 10.4236/jct.2015.67061 10.1002/bod.2510090402 10.1007/s00280-018-3654-0 10.1124/dmd.108.024901 |
| ContentType | Journal Article |
| Copyright | Springer-Verlag GmbH Germany, part of Springer Nature 2018 Cancer Chemotherapy and Pharmacology is a copyright of Springer, (2018). All Rights Reserved. |
| Copyright_xml | – notice: Springer-Verlag GmbH Germany, part of Springer Nature 2018 – notice: Cancer Chemotherapy and Pharmacology is a copyright of Springer, (2018). All Rights Reserved. |
| DBID | AAYXX CITATION NPM 3V. 7TO 7X7 7XB 88E 8AO 8C1 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.1007/s00280-018-3730-5 |
| DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Oncogenes and Growth Factors Abstracts PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1432-0843 |
| EndPage | 275 |
| ExternalDocumentID | 30430227 10_1007_s00280_018_3730_5 |
| Genre | Journal Article |
| GroupedDBID | --- -53 -56 -5G -BR -EM -~C .86 .VR 06C 06D 0R~ 0VY 1N0 203 29B 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2~H 30V 36B 4.4 406 408 409 40D 40E 5GY 5RE 5VS 67Z 6NX 6PF 78A 7X7 88E 8AO 8C1 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANZL AARTL AASML AATNV AATVU AAUYE AAWCG AAWTL AAYIU AAYQN AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABSXP ABTEG ABTKH ABTMW ABUWG ABUWZ ABWNU ABXPI ACAOD ACDTI ACGFS ACHSB ACHVE ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEFQL AEGAL AEGNC AEJHL AEJRE AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFJLC AFKRA AFLOW AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BDATZ BENPR BGNMA BPHCQ BSONS BVXVI CCPQU CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMB EMOBN ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GXS HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KPH LAS LLZTM M1P M4Y MA- MK0 N9A NB0 NPVJJ NQJWS NU0 O93 O9G O9I O9J OAM P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R89 R9I RHV RNS ROL RPX RRX RSV S16 S27 S37 S3B SAP SBL SDH SDM SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 YLTOR Z45 Z7U Z82 Z83 Z87 Z8O Z8V Z8W Z91 ZMTXR ZOVNA ~EX ~KM -Y2 .GJ 1SB 2.D 28- 2P1 2VQ 3O- 53G 5QI AANXM AAPKM AARHV AAYTO AAYXX ABBRH ABDBE ABFSG ABQSL ABRTQ ABULA ACBXY ACSTC ACUDM ADHKG AEBTG AEFIE AEKMD AEZWR AFDYV AFDZB AFEXP AFFHD AFFNX AFHIU AFOHR AGGDS AGQPQ AHPBZ AHWEU AIXLP AJBLW ATHPR AYFIA BBWZM CAG CITATION COF EN4 GRRUI H13 KOW N2Q NDZJH O9- PHGZM PHGZT PJZUB PPXIY R4E RNI RZK S1Z S26 S28 SCLPG SDE T16 Y6R ZGI 3V. NPM RIG 7TO 7XB 8FK H94 K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO |
| ID | FETCH-LOGICAL-c372t-42d3d060048902eba8b8799f633d80065adfd8ca256f8332ecea6e44612565ab3 |
| IEDL.DBID | RSV |
| ISICitedReferencesCount | 24 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000459155300004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0344-5704 1432-0843 |
| IngestDate | Fri Sep 05 08:08:49 EDT 2025 Sat Nov 08 14:41:17 EST 2025 Wed Feb 19 02:34:40 EST 2025 Sat Nov 29 04:45:33 EST 2025 Tue Nov 18 22:23:55 EST 2025 Fri Feb 21 02:33:12 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Cancer patients Curcumin Co-medications Pharmacokinetics Tetrahydrocurcumin |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c372t-42d3d060048902eba8b8799f633d80065adfd8ca256f8332ecea6e44612565ab3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 |
| PMID | 30430227 |
| PQID | 2133076420 |
| PQPubID | 48447 |
| PageCount | 11 |
| ParticipantIDs | proquest_miscellaneous_2133826040 proquest_journals_2133076420 pubmed_primary_30430227 crossref_citationtrail_10_1007_s00280_018_3730_5 crossref_primary_10_1007_s00280_018_3730_5 springer_journals_10_1007_s00280_018_3730_5 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-02-01 |
| PublicationDateYYYYMMDD | 2019-02-01 |
| PublicationDate_xml | – month: 02 year: 2019 text: 2019-02-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Berlin/Heidelberg |
| PublicationPlace_xml | – name: Berlin/Heidelberg – name: Germany – name: Heidelberg |
| PublicationTitle | Cancer chemotherapy and pharmacology |
| PublicationTitleAbbrev | Cancer Chemother Pharmacol |
| PublicationTitleAlternate | Cancer Chemother Pharmacol |
| PublicationYear | 2019 |
| Publisher | Springer Berlin Heidelberg Springer Nature B.V |
| Publisher_xml | – name: Springer Berlin Heidelberg – name: Springer Nature B.V |
| References | Helson, Bolger, Majeed, Vcelar, Pucaj, Matabudul (CR17) 2012; 32 Niles, Hofmann, Resch, Schaeffeler, Rius, Schwab (CR27) 2011; 6 Cossum (CR29) 1988; 9 Oostendorp, van de Steeg, van der Kruijssen, Beijnen, Kenworthy, Schinkel (CR26) 2009; 37 Sánchez, Giménez, Miglorini, Giannone, Ramirez, Weder (CR36) 1997; 30 Gosh, Kay, Secreto, Shanafelt (CR7) 2009; 15 Sánchez, Giménez, Gilbert, Giannone, Marco, Ramirez (CR34) 1991; 17 Storka, Vcelar, Klickovic, Gouya, Weisshaar, Aschauer (CR37) 2013; 33 Kato, Ishida, Matsusaka, Ishimaru, Tanimoto, Sugiyama (CR33) 2015; 10 Dhillon, Aggarwal, Newman, Wolfe, Kunnumakkara, Abbruzzese (CR3) 2008; 14 Mohanram, Zhang, Shahinfar, Lyle, Toto (CR31) 2008; 73 Yang, Lin, Tseng, Wang, Tsai (CR15) 2007; 853 Tan, Wu, Wong, Licollari, Bolger, Fanaras (CR24) 2016; 1028 Huang, Li, Zhang, Tan, Lu, Liu (CR25) 2015; 9 Garcea, Jones, Singh, Dennison, Farmer, Sharma (CR9) 2004; 90 Greil, Greil-Ressler, Weiss, Schönlieb, Magnes, Radl (CR23) 2018; 82 Pratt, Lewis-Barned, Walker, Bailey, Shand, Livesey (CR30) 1992; 34 Herlitz, Dahlöf, Jonsson, Hansson (CR35) 1994; 8 Gutierres, Campos, Aracar, Assis, Baldan-Cimatti, Peccinini (CR18) 2015 Zhongfa, Chiu, Wang, Chen, Yen, Fan-Havard (CR10) 2012; 69 Priyadarsini (CR12) 2014; 19 Chang, Chuang, Hsu, Liu, Gambhir, Hwant (CR5) 2012; 5 Bhattacharyya, Hossain, Mohanty, Senj, Chattopadhyay, Banerjee, Chankraborty, Das, Dptendra, Das, Gaurisankar (CR6) 2010; 7 Rajan, Mukerjee, Helson, Gupta, Vishwanatha (CR22) 2013; 33 Prasad, Tyagi, Aggarwal (CR11) 2014; 46 Bolger, Licollari, Tan, Griel, Vcelar, Majeed (CR20) 2017; 37 Sharma, McLelland, Hill, Ireson, Euden, Manson (CR1) 2001; 7 Pan, Sy, Lin (CR14) 2000; 60 Zhou, Zhang, Chen, Guo, Liu, Yu (CR28) 2016; 47 Chen, Hsu, Lin, Hsu, Ho, Shen (CR2) 2001; 21 Kim, Mungunsukh, McCart, Roehrich, Yee, Day (CR32) 2014; 85 Tsai, Chien, Lin, Tsai (CR16) 2011; 416 Storka, Vcelar, Klickovic, Gouya, Weisshaar, Aschauer (CR19) 2015; 53 Li, Zhang, Hill, Wang, Zhang (CR4) 2007; 67 Everett, Meyers, Makkinje, Rabbi, Lerner (CR8) 2007; 82 Wang, Pan, Cheng, Lin, Ho, Hsieh (CR13) 1997; 15 Golombick, Diamon, Manoharan, Ramakrishna (CR21) 2015; 6 AK Gosh (3730_CR7) 2009; 15 A Storka (3730_CR37) 2013; 33 K-Y Yang (3730_CR15) 2007; 853 S Bhattacharyya (3730_CR6) 2010; 7 GT Bolger (3730_CR20) 2017; 37 X Zhou (3730_CR28) 2016; 47 T Golombick (3730_CR21) 2015; 6 MH Pan (3730_CR14) 2000; 60 A Mohanram (3730_CR31) 2008; 73 M Li (3730_CR4) 2007; 67 G Garcea (3730_CR9) 2004; 90 AP Rajan (3730_CR22) 2013; 33 RA Sánchez (3730_CR36) 1997; 30 A Tan (3730_CR24) 2016; 1028 H Herlitz (3730_CR35) 1994; 8 Z Huang (3730_CR25) 2015; 9 A Storka (3730_CR19) 2015; 53 Y-C Kim (3730_CR32) 2014; 85 RA Sharma (3730_CR1) 2001; 7 R Greil (3730_CR23) 2018; 82 PA Cossum (3730_CR29) 1988; 9 RL Oostendorp (3730_CR26) 2009; 37 PC Everett (3730_CR8) 2007; 82 AL Chen (3730_CR2) 2001; 21 KI Priyadarsini (3730_CR12) 2014; 19 Y-M Tsai (3730_CR16) 2011; 416 AT Niles (3730_CR27) 2011; 6 RA Sánchez (3730_CR34) 1991; 17 S Prasad (3730_CR11) 2014; 46 MC Pratt (3730_CR30) 1992; 34 H Kato (3730_CR33) 2015; 10 Y-J Wang (3730_CR13) 1997; 15 VO Gutierres (3730_CR18) 2015 L Zhongfa (3730_CR10) 2012; 69 L Helson (3730_CR17) 2012; 32 D Dhillon (3730_CR3) 2008; 14 Y-F Chang (3730_CR5) 2012; 5 |
| References_xml | – volume: 90 start-page: 1011 year: 2004 end-page: 1015 ident: CR9 article-title: Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration publication-title: Brit J Cancer doi: 10.1038/sj.bjc.6601623 – volume: 9 start-page: 4319 year: 2015 end-page: 4328 ident: CR25 article-title: Characterization of preclinical in vitro and in vivo pharmacokinetic properties for KBP-7018, a new tyrosine kinase inhibitor candidate for treatment of idiopathic pulmonary fibrosis publication-title: Drug Des Dev Ther – volume: 853 start-page: 183 year: 2007 end-page: 189 ident: CR15 article-title: Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC–MS/MS publication-title: J Chromatograph B doi: 10.1016/j.jchromb.2007.03.010 – volume: 21 start-page: 2895 year: 2001 end-page: 2900 ident: CR2 article-title: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions publication-title: Anticancer Res – volume: 7 start-page: 1894 year: 2001 end-page: 1900 ident: CR1 article-title: Pharmacodynamic and pharmacokinetic study of oral curcuma extract in patients with colorectal cancer publication-title: Clin Cancer Res – year: 2015 ident: CR18 article-title: Curcumin pharmacokinetics and pharmacodynamic evidences in streptozotocin-diabetic rats support the antidiabetic activity to be via metabolites publication-title: Evid Based Complement Altern Med doi: 10.1155/2015/678218 – volume: 37 start-page: 3483 year: 2017 end-page: 3492 ident: CR20 article-title: Distribution and metabolism of Lipocurc™ (Liposomal curcumin) in dog and human blood cells: species selectivity and pharmacokinetic relevance publication-title: Anticancer Res – volume: 7 start-page: 6306 year: 2010 end-page: 6315 ident: CR6 article-title: Curcumin reverses T cell-mediated adaptive immune dysfunctions in tumor-bearing hosts publication-title: Cell Mol Immunol doi: 10.1038/cmi.2010.11 – volume: 17 start-page: 331 year: 1991 end-page: 334 ident: CR34 article-title: Recovery of erythrocyte Na –K –Cl cotransport activity by enalapril publication-title: Hypertension doi: 10.1161/01.HYP.17.3.334 – volume: 60 start-page: 1665 year: 2000 end-page: 1676 ident: CR14 article-title: Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through down-regulation of IkappaB kinase and NFkappaB activation in macrophages publication-title: Biochem Pharmacol doi: 10.1016/S0006-2952(00)00489-5 – volume: 53 start-page: 54 year: 2015 end-page: 65 ident: CR19 article-title: Safety, tolerability and pharmacokinetics of liposomal curcumin (Lipocurc™) in healthy humans publication-title: Int J Clin Pharmacol Ther doi: 10.5414/CP202076 – volume: 6 start-page: e22163 issue: 7 year: 2011 ident: CR27 article-title: Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs) publication-title: PLoS One doi: 10.1371/journal.pone.0022163 – volume: 10 start-page: e0129484 issue: 6 year: 2015 ident: CR33 article-title: Erythropoiesis and blood pressure are regulated via AT1 receptor by distinctive pathways publication-title: PLoS One doi: 10.1371/journal.pone.0129484 – volume: 15 start-page: 1250 year: 2009 end-page: 1258 ident: CR7 article-title: Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with ECGC publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-08-1511 – volume: 85 start-page: 898 year: 2014 end-page: 908 ident: CR32 article-title: Mechanism of erythropoietin regulation by angiotensin II publication-title: Mol Pharmacol doi: 10.1124/mol.113.091157 – volume: 47 start-page: 267 year: 2016 end-page: 275 ident: CR28 article-title: Impact of curcumin on the pharmacokinetics of rousuvastatin in rats and dogs based on the conjugated metabolites publication-title: Xenobiotica doi: 10.1080/00498254.2016.1183060 – volume: 5 start-page: 444 year: 2012 end-page: 452 ident: CR5 article-title: Immunomodulation of curcumin on adoptive therapy with t cell functional imaging in mice publication-title: Cancer Prev Res doi: 10.1158/1940-6207.CAPR-11-0308 – volume: 73 start-page: 630 year: 2008 end-page: 636 ident: CR31 article-title: The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes publication-title: Kidney Int doi: 10.1038/sj.ki.5002746 – volume: 15 start-page: 1867 year: 1997 end-page: 1976 ident: CR13 article-title: Stability of curcumin in buffer solutions and characterization of its degradation products publication-title: J Phamaceut Biomed Anal doi: 10.1016/S0731-7085(96)02024-9 – volume: 33 start-page: 3603 year: 2013 end-page: 3609 ident: CR22 article-title: Efficacy of liposomal curcumin in a human pancreatic tumor xenograft model: inhibition of tumor growth and angiogenesis publication-title: Anticancer Res – volume: 69 start-page: 679 year: 2012 end-page: 689 ident: CR10 article-title: Enhancement of curcumin oral absorption and pharmacokinetics of curcuminoids and curcumin metabolites in mice publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-011-1749-y – volume: 19 start-page: 20091 year: 2014 end-page: 20112 ident: CR12 article-title: The chemistry of curcumin: from extraction to therapeutic agent publication-title: Molecules doi: 10.3390/molecules191220091 – volume: 46 start-page: 2 year: 2014 end-page: 18 ident: CR11 article-title: Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice publication-title: Cancer Res Treat doi: 10.4143/crt.2014.46.1.2 – volume: 416 start-page: 331 year: 2011 end-page: 338 ident: CR16 article-title: Curcumin and its nano-formulation: the kinetics of tissue distribution and blood–brain barrier penetration publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2011.06.030 – volume: 34 start-page: 363 year: 1992 end-page: 365 ident: CR30 article-title: Effects of angiotensin converting enzyme inhibitors on erythropoietin concentrations in health volunteers publication-title: Br J Clin Pharm doi: 10.1111/j.1365-2125.1992.tb05644.x – volume: 33 start-page: 3629 year: 2013 end-page: 3634 ident: CR37 article-title: Effect of liposomal curcumin on red blood cells in vitro publication-title: Anticancer Res – volume: 1028 start-page: 86 year: 2016 end-page: 93 ident: CR24 article-title: Use of basic mobile phase to improve chromatography and boost sensitivity for quantifying tetrahydrocurcumin in human plasma by LC–MS/MS publication-title: J Chromatograph B doi: 10.1016/j.jchromb.2016.06.010 – volume: 67 start-page: 1988 year: 2007 end-page: 1996 ident: CR4 article-title: Curcumin, a dietary component, has anticancer chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3/mTOR/ETS2 pathway publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-06-3066 – volume: 14 start-page: 4491 year: 2008 end-page: 4499 ident: CR3 article-title: Phase II trial of curcumin in patients with advanced pancreatic cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-08-0024 – volume: 30 start-page: 99 year: 1997 end-page: 105 ident: CR36 article-title: Erythrocyte sodium-lithium countertransport in non modulating offspring and essential hypertensive individuals publication-title: Response Enalapril Hypertens doi: 10.1161/01.HYP.30.1.99 – volume: 82 start-page: 23 year: 2007 end-page: 30 ident: CR8 article-title: Preclinical assessment of curcumin as a potential therapy for B-CLL publication-title: Am J Hematol doi: 10.1002/ajh.20757 – volume: 6 start-page: 566 year: 2015 end-page: 571 ident: CR21 article-title: The effects of curcumin (as Meriva) on absolute lymphocyte count (ALC), NK cells and T cell populations in patients with stage 0/1 chronic lymphocytic leukemia publication-title: J Cancer Ther doi: 10.4236/jct.2015.67061 – volume: 9 start-page: 321 year: 1988 end-page: 336 ident: CR29 article-title: Role of the red blood cell in drug metabolism publication-title: Biopharm Drug Dispos doi: 10.1002/bod.2510090402 – volume: 32 start-page: 4365 year: 2012 end-page: 4370 ident: CR17 article-title: Infusion pharmacokinetics of Lipocurc™ (liposomal curcumin) and its metabolite tetrahydrocurcumin in beagle dogs publication-title: Anticancer Res – volume: 8 start-page: 837 year: 1994 end-page: 841 ident: CR35 article-title: Relationship between change in erythrocyte sodium and antihypertensive response to enalapril publication-title: J Hum Hypertens – volume: 82 start-page: 695 year: 2018 end-page: 706 ident: CR23 article-title: A phase 1 dose escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc™) in patients with locally advanced or metastatic cancer publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-018-3654-0 – volume: 37 start-page: 917 year: 2009 end-page: 923 ident: CR26 article-title: Organic anion-transporting polypeptide 1B1 mediates transport of bimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors publication-title: Drug Metab Dispos doi: 10.1124/dmd.108.024901 – year: 2015 ident: 3730_CR18 publication-title: Evid Based Complement Altern Med doi: 10.1155/2015/678218 – volume: 30 start-page: 99 year: 1997 ident: 3730_CR36 publication-title: Response Enalapril Hypertens doi: 10.1161/01.HYP.30.1.99 – volume: 85 start-page: 898 year: 2014 ident: 3730_CR32 publication-title: Mol Pharmacol doi: 10.1124/mol.113.091157 – volume: 5 start-page: 444 year: 2012 ident: 3730_CR5 publication-title: Cancer Prev Res doi: 10.1158/1940-6207.CAPR-11-0308 – volume: 37 start-page: 3483 year: 2017 ident: 3730_CR20 publication-title: Anticancer Res – volume: 1028 start-page: 86 year: 2016 ident: 3730_CR24 publication-title: J Chromatograph B doi: 10.1016/j.jchromb.2016.06.010 – volume: 6 start-page: 566 year: 2015 ident: 3730_CR21 publication-title: J Cancer Ther doi: 10.4236/jct.2015.67061 – volume: 53 start-page: 54 year: 2015 ident: 3730_CR19 publication-title: Int J Clin Pharmacol Ther doi: 10.5414/CP202076 – volume: 34 start-page: 363 year: 1992 ident: 3730_CR30 publication-title: Br J Clin Pharm doi: 10.1111/j.1365-2125.1992.tb05644.x – volume: 82 start-page: 695 year: 2018 ident: 3730_CR23 publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-018-3654-0 – volume: 90 start-page: 1011 year: 2004 ident: 3730_CR9 publication-title: Brit J Cancer doi: 10.1038/sj.bjc.6601623 – volume: 10 start-page: e0129484 issue: 6 year: 2015 ident: 3730_CR33 publication-title: PLoS One doi: 10.1371/journal.pone.0129484 – volume: 60 start-page: 1665 year: 2000 ident: 3730_CR14 publication-title: Biochem Pharmacol doi: 10.1016/S0006-2952(00)00489-5 – volume: 73 start-page: 630 year: 2008 ident: 3730_CR31 publication-title: Kidney Int doi: 10.1038/sj.ki.5002746 – volume: 69 start-page: 679 year: 2012 ident: 3730_CR10 publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-011-1749-y – volume: 15 start-page: 1867 year: 1997 ident: 3730_CR13 publication-title: J Phamaceut Biomed Anal doi: 10.1016/S0731-7085(96)02024-9 – volume: 15 start-page: 1250 year: 2009 ident: 3730_CR7 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-08-1511 – volume: 67 start-page: 1988 year: 2007 ident: 3730_CR4 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-06-3066 – volume: 19 start-page: 20091 year: 2014 ident: 3730_CR12 publication-title: Molecules doi: 10.3390/molecules191220091 – volume: 9 start-page: 321 year: 1988 ident: 3730_CR29 publication-title: Biopharm Drug Dispos doi: 10.1002/bod.2510090402 – volume: 47 start-page: 267 year: 2016 ident: 3730_CR28 publication-title: Xenobiotica doi: 10.1080/00498254.2016.1183060 – volume: 8 start-page: 837 year: 1994 ident: 3730_CR35 publication-title: J Hum Hypertens – volume: 7 start-page: 6306 year: 2010 ident: 3730_CR6 publication-title: Cell Mol Immunol doi: 10.1038/cmi.2010.11 – volume: 416 start-page: 331 year: 2011 ident: 3730_CR16 publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2011.06.030 – volume: 37 start-page: 917 year: 2009 ident: 3730_CR26 publication-title: Drug Metab Dispos doi: 10.1124/dmd.108.024901 – volume: 7 start-page: 1894 year: 2001 ident: 3730_CR1 publication-title: Clin Cancer Res – volume: 82 start-page: 23 year: 2007 ident: 3730_CR8 publication-title: Am J Hematol doi: 10.1002/ajh.20757 – volume: 853 start-page: 183 year: 2007 ident: 3730_CR15 publication-title: J Chromatograph B doi: 10.1016/j.jchromb.2007.03.010 – volume: 6 start-page: e22163 issue: 7 year: 2011 ident: 3730_CR27 publication-title: PLoS One doi: 10.1371/journal.pone.0022163 – volume: 9 start-page: 4319 year: 2015 ident: 3730_CR25 publication-title: Drug Des Dev Ther – volume: 21 start-page: 2895 year: 2001 ident: 3730_CR2 publication-title: Anticancer Res – volume: 33 start-page: 3629 year: 2013 ident: 3730_CR37 publication-title: Anticancer Res – volume: 33 start-page: 3603 year: 2013 ident: 3730_CR22 publication-title: Anticancer Res – volume: 46 start-page: 2 year: 2014 ident: 3730_CR11 publication-title: Cancer Res Treat doi: 10.4143/crt.2014.46.1.2 – volume: 14 start-page: 4491 year: 2008 ident: 3730_CR3 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-08-0024 – volume: 32 start-page: 4365 year: 2012 ident: 3730_CR17 publication-title: Anticancer Res – volume: 17 start-page: 331 year: 1991 ident: 3730_CR34 publication-title: Hypertension doi: 10.1161/01.HYP.17.3.334 |
| SSID | ssj0004133 |
| Score | 2.3706043 |
| Snippet | Purpose
Investigation of the impact of co-medication on the plasma levels of curcumin and tetrahydrocurcumin (THC) in cancer patients and a comparison of the... Investigation of the impact of co-medication on the plasma levels of curcumin and tetrahydrocurcumin (THC) in cancer patients and a comparison of the... PurposeInvestigation of the impact of co-medication on the plasma levels of curcumin and tetrahydrocurcumin (THC) in cancer patients and a comparison of the... |
| SourceID | proquest pubmed crossref springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 265 |
| SubjectTerms | Angiotensin Cancer Cancer Research Correlation analysis Curcumin Data processing Erythrocytes Intravenous administration Medicine Medicine & Public Health Oncology Original Article Pharmacokinetics Pharmacology/Toxicology Plasma Plasma levels Renin |
| SummonAdditionalLinks | – databaseName: Public Health Database dbid: 8C1 link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbtQwEB5BQagXfspfoCAjoQpoLbx2fhwuCFVUHKDaQ5F6ixzbkVa0yXazQdo7L8Ar8Gg8CePYSYQqeuHoxI4t-ZvJjGf8DcBLk4sUPR9OlUoVjW1qaM4Np0wlpc2MjCtV9sUmsuNjeXqaz8OBWxvSKged2Ctq02h3Rv6WozOFPnfM2fvlBXVVo1x0NZTQuA43ZpzFTjDl4ZTigQral0eOY5pkLB6imqwnEeXSpWRJFDHBaPL3f-mSsXkpUNr_f47u_O_K78LtYHmSDx4q9-CarXfg1pcQW9-Bvblnsd4ckJPpUlZ7QPbIfOK33tyHn0PzG45zXUhTkbPFsmmbc5xAdyvdnS9q8uozPnOt3z9-vSaI5M6dzL0jPoXEDdIN7WP7PTqwB9EOgysSyF5bompD9FgpkbhDY-Jvbm7IYrxK1j6Ar0cfTw4_0VDZgWqR8TWNuRGGpU595IzbUslSZnleIWyMdFaRMpWRWqE9VkkhuNVWpRY9VzTH8GUpHsJW3dT2MRA0P7Q2VsxmJbq6plS2FLOkNAg17djwImDDvhY60J676htnxUjY3EOhQCgUDgpFEsGbccjSc35c1Xl32PUiiH9bTFsewYvxNQqui8ao2jad74O-HSrRCB55kI2zCcfExnkWwf6Auunj_1zKk6uX8hS20drLfcr5LmytV519Bjf19_WiXT3vJecPpnMgYA priority: 102 providerName: ProQuest |
| Title | Pharmacokinetics of liposomal curcumin (Lipocurc™) infusion: effect of co-medication in cancer patients and comparison with healthy individuals |
| URI | https://link.springer.com/article/10.1007/s00280-018-3730-5 https://www.ncbi.nlm.nih.gov/pubmed/30430227 https://www.proquest.com/docview/2133076420 https://www.proquest.com/docview/2133826040 |
| Volume | 83 |
| WOSCitedRecordID | wos000459155300004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1432-0843 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0004133 issn: 0344-5704 databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB7RFiEuPMorUFZGQhWPWkrsJHa4QdWKA6xWpaC9RY7tSCvapNpskPbOH-Av8NP4JYzjJCtUQIJLJMfjh-Rv7BmPZwbgqcl4ipoPo0qlisY2NTRjhtFQJYUVRsalKrpkE2I6lfN5Nuv9uJvhtftgkux26tHZrbMCouorkSl4SJMt2MHTTjpuPPnwaeMMGfn88TyOaSLCeDBl_q6LXw-jSxLmJetod-gc3_yv6d6CG72MSV57UNyGK7bahWvveyv6LuzPfLzq9QE53bhfNQdkn8w2kazXd-DbUPyM7RwJqUtytriom_ocB9DtUrfni4o8e4f_XOnH1-_PCWK2dXdwr4h_LOIa6Zp2VvwOB0hBtEPbkvRhXRuiKkP0mBORuOth4n0012QxOo01d-Hj8dHp4Vva53Cgmgu2ojEz3ISp2yiykNlCyUKKLCsRIEY6-UeZ0kitUPIqJefMaqtSizoqCl5YWfB7sF3VlX0ABAUNrY3lUVSgUmsKZQseJYVBUGkX9y6AcFjMXPcBzl2ejbN8DM3crUmOa5K7NcmTAF6MTS58dI-_Ee8NCMl7Rm9yhmgLBSpxYQBPxmpkUWd3UZWtW0-DWhxulwHc98gaR-Mu5hpjIoCXA4w2nf9xKg__ifoRXEcxL_Nvzfdge7Vs7WO4qr-sFs1yAltiLrqvxK88jCaw8-ZoOjuZdHz1EzCEGmc |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3NbtQwEB6VgoALP4VCoICRoAJai6ydXySEEFC16na1h0XaW3BsR1rRJstmA9o7L8Ar8AA8FE_COM6PUEVvPXBMYieW8814xp75BuCJinmAng-jQgSCejpQNGaKUVf4qQ5V5GUirYtNhKNRNJ3G4zX41ebCmLDKVifWiloV0uyRv2ToTKHP7TH3zfwLNVWjzOlqW0LDwuJQr76hy1a-PniP__cpY3sfJu_2aVNVgEoesiX1mOLKDQx0Y5fpVERpFMZxhkNWkVmRhcpUJAXaAlnEOdNSi0Cj14SmAD5MOb73AlxEPR6aELJwGvZ5mANbup57HvVD12tPUd2atJRFJgQsQpHmLvX_XgdPGbenDmbr9W7v-v82UzfgWmNZk7dWFG7Cms434PJREzuwAdtjy9K92iWTPums3CXbZNzzd69uwY_28jP2M01IkZHj2bwoixP8gKwWsjqZ5eTZEO-Zq9_ffz4nKKmV2Xl8RWyIjOkkC1rHLtToxxZEGhlbkIbMtiQiV0R2lSCJ2RQnNjN1RWZdqlx5Gz6ey8xtwnpe5PouEDSvpFSaDwYpuvIqFTrlAz9VKErSsP054LY4SmRD626qixwnHSF1Db0EoZcY6CW-Ay-6LnPLaXJW460WZUmj3sqkh5gDj7vHqJjMaZPIdVHZNui74iLhwB0L6u5r3DDNMRY6sNOivH_5P4dy7-yhPIIr-5OjYTI8GB3eh6to2cY2vH4L1peLSj-AS_LrclYuHtZSS-DTeYP_D92JfCM |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3NbtQwEB6Vgiou_JS_QAEjQcVPrWbtJE6QEEKUFVXLag9F2ltwbEda0SbLZgPaOy_AK_AYPA5PwjhOskIVvfXA0YntWM439ow98w3AY53wCC0fRqWMJA1MpGnCNKO-DDMjdBzkMmuSTYjRKJ5MkvEa_OpiYaxbZbcmNgu1LpU9I99laEyhzR0wfzdv3SLGe8PXsy_UZpCyN61dOg0HkQOz_IbmW_Vqfw__9RPGhu-O3r6nbYYBqrhgCxowzbUfWRgnPjOZjLNYJEmOw9ex3Z2lznWsJOoFecw5M8rIyKAFhWoBvsw49nsBLgrOhU0bISZiFZM5cGnseRDQUPhBd6PqNwSmLLbuYDGKN_dp-PeeeErRPXVJ2-x9w6v_86xdgyutxk3eOBG5Dmum2ISND61PwSZsjx1793KHHK2C0aodsk3GK17v5Q340RU_YztbhZQ5OZ7Oyqo8wQ-oeq7qk2lBnh7iM1v6_f3nM4ISXNsTyZfEuc7YRqqkjU9DIxVYgygre3PSktxWRBaaqD5DJLGH5cRFrC7JtA-hq27Cx3OZuVuwXpSFuQME1S6ltOGDQYYmvs6kyfggzDSKmLIsgB74HaZS1dK926wjx2lPVN3AMEUYphaGaejB877JzHGdnFV5q0Nc2i57VbqCmweP-te4YNlbKFmYsnZ10KbFzcOD2w7g_de4ZaBjTHjwokP8qvN_DuXu2UN5CBuI-fRwf3RwDy6jwps4r_stWF_Ma3MfLqmvi2k1f9AIMIFP5439PyBzhNc |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacokinetics+of+liposomal+curcumin+%28Lipocurc%E2%84%A2%29+infusion%3A+effect+of+co-medication+in+cancer+patients+and+comparison+with+healthy+individuals&rft.jtitle=Cancer+chemotherapy+and+pharmacology&rft.au=Bolger%2C+Gordon+T&rft.au=Licollari%2C+Albert&rft.au=Tan%2C+Amin&rft.au=Greil%2C+Richard&rft.date=2019-02-01&rft.issn=1432-0843&rft.eissn=1432-0843&rft.volume=83&rft.issue=2&rft.spage=265&rft_id=info:doi/10.1007%2Fs00280-018-3730-5&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0344-5704&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0344-5704&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0344-5704&client=summon |